YANTAI, China, Feb. 2, 2024 /PRNewswire/ -- RemeGen Co. Ltd.("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, with a mission that is closely aligned with the Close the Care Gap theme of World Cancer Day 2024 which falls on February 4, has announced three major developments that will further the global fight against cancer and forge new paths in tumor treatments. The Company not only endeavors to contribute to the field of anti-cancer treatments, but also provide much-improved medical opportunities and increased hope to all patients.
Dr. Jianmin Fang, CEO of RemeGen, commented, "Cancer is the common enemy of mankind, and at RemeGen we feel a strong sense of responsibility and mission to continue to provide more effective and safer treatment options for cancer patients around the world through our cutting-edge innovation and research. On World Cancer Day 2024, we are proud to announce more advances in cancer drug research through drug discovery and collaboration with our partners. We are celebrating the progress of scientific research and working for a more just and healthier future. Our time is now, and our mission is clear. Let's act together for a world without cancers."
On January 12, RemeGen announced that it enrolled its first patient on a Phase II study of Disitamab Vedotin combined with Zimberelimab to treat cervical cancer patients who have failed at least one first-line platinum-containing standard treatment. Preliminary data show that Disitamab Vedotin can significantly improve treatment efficiency and its safety is controllable. Zimberelimab, compared with the data of PD-1/PD-L1 single drugs approved for this indication (not head-to-head), displayed excellent long-term efficacy with a higher objective response rate (ORR) of 27.8%, a median progression-free survival (mPFS) of 3.7 months, a median overall survival (mOS) of 16.8 months, and a 2-year duration of response (DoR) rate of 55%. This study is a new combination treatment strategy that is expected to provide better options for cervical cancer patients and bring new hope.
World Cancer Day is a leading international awareness day held every February 4 and is the global uniting initiative led by the Union for International Cancer Control (UICC). By raising worldwide awareness, improving education and catalyzing personal, collective and government action, organizers all work together to reimagine a world where millions of preventable cancer deaths are saved and access to life-saving cancer treatment and care is equitable for all - no matter who you are or where you live.
Founded in 2008, RemeGen (9995.HK, SHA: 688331) is a leading biopharmaceutical company in China committed to providing solutions to the unmet clinical needs of patients suffering from life-threatening illnesses. RemeGen has research laboratories and offices throughout China and the United States. The company is committed to discovering, developing, and commercializing innovative and differentiated biologic drugs of significant clinical value in the key therapeutic areas of autoimmune, oncology, and ophthalmic diseases.
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.